enVVeno Medical (NVNO) EBITDA (2017 - 2026)

enVVeno Medical's EBITDA history runs 10 years deep, the most recent figure standing at -$4.1 million for Q1 2026.

• On a quarterly basis, EBITDA rose 18.01% year-over-year to -$4.1 million in Q1 2026; TTM through Mar 2026 was -$20.0 million, a 14.05% increase from a year earlier, with the FY2025 full-year figure at -$20.9 million, up 12.28% from the prior year.
• EBITDA fell to -$4.1 million in Q1 2026 per NVNO's latest filing, from -$4.0 million in the prior quarter.
• Across five years, EBITDA topped out at -$4.0 million in Q4 2025 and bottomed at -$7.0 million in Q2 2025.
• The 5-year median for EBITDA is -$6.2 million (2022), against an average of -$5.8 million.
• Across the five-year window, EBITDA plunged 192.79% in 2022 and soared 40.1% in 2025, its largest moves.
• Year by year, EBITDA stood at -$6.5 million in 2022, then increased by 2.82% to -$6.3 million in 2023, then slipped by 6.71% to -$6.7 million in 2024, then surged by 40.1% to -$4.0 million in 2025, then dropped by 1.22% to -$4.1 million in 2026.
• Per Business Quant, the three latest NVNO EBITDA figures stand at -$4.1 million (Q1 2026), -$4.0 million (Q4 2025), and -$4.9 million (Q3 2025).